Episode Details

ICLR Stock: BUY Call - Accounting Cloud Lifts +17% Q1 2026 ICON plc (NASDAQ: ICLR), one of the world's two largest clinical-research organizations, jumped roughly +17% as its accounting investigation finally cleared. Revenue came in at $2,112.5M (+3.5% YoY), beating the ~$1.99B Street estimate, while adjusted EPS of $2.52 missed the ~$3.12 consensus on margin compression. The decisive catalyst: the audit committee review found revenue overstatements across 2023-2025 all below the 2% upper bound and no fraud - lifting the overhang that had crushed the stock from above $200 to the low $80s. VERDICT: BUY (Conviction 4/5 STRONG) - Buy below $130 | Hard stop $95 | Trim above $190 - Current price $136.80 | post-print +16.85% KEY METRICS Q1 2026: - Revenue: $2,112.5M (+3.5% YoY, ~6% beat) - Adjusted EPS: $2.52 vs ~$3.12 Street (miss on margin compression) - Operating Margin: ~12% - Net Book-to-Bill: 1.36x - Total Backlog: $21.8B (revised methodology) - Free Cash Flow: ~$325M (mid-teens margin) - FY2025 Buyback: $750M (share count 83M -> 76M over 8 quarters) GUIDANCE FY2026: - Revenue: $7.85B - $8.15B (midpoint roughly Street) - Adjusted EPS: $10.00 - $11.00 (transition year, below $11.28 Street) CEO Barry Balfe: "With the audit committee review now complete and the impact contained, we are focused squarely on converting our strong backlog and rebuilding momentum across the business." Charged Alpha is more bullish than consensus: at 12-13x forward earnings the equity prices in permanent stagnation, but a $21.8B backlog and a 1.36 book-to-bill say new work is still flowing in faster than revenue is burning. Not Financial Advice - Informational Only